Epidemiological and clinical characteristics of bacteremic brucellosis

Chunhua Qie1,*, Junwen Cui2,*, Yamin Liu3, Ying Li3, Hongzhang Wu1 and Yuqiang Mi3

Abstract
Objective: To retrospectively investigate the epidemiological features, clinical manifestations and laboratory characteristics of bacteremic brucellosis.

Methods: Brucellosis patients admitted to our clinic from January 2015 to December 2017 were included in the study. Patient electronic medical records were reviewed for epidemiological features, clinical manifestations, and laboratory findings.

Results: A total of 132 brucellosis patients were analyzed (64 cases with bacteremic brucellosis and 68 cases with nonbacteremic brucellosis). The median duration from exposure to onset of symptoms was 6.9 weeks (range: 1 day to 32 weeks) and 21.9 weeks (range: 1–76 weeks) in patients with bacteremic and nonbacteremic brucellosis, respectively. More bacteremic than nonbacteremic patients presented with fever and chills. Arthritis was observed in 34 (25.8%) patients, and was more commonly observed in nonbacteremic patients. Using C-reactive protein (CRP) and procalcitonin (PCT) as serological markers, the areas under the receiving operating characteristic curves were 0.64 [95% confidence interval (CI): 0.54–0.73] and 0.61 (95% CI: 0.51–0.70), respectively, for distinguishing bacteremic from non-bacteremic brucellosis.

Conclusion: Fever and chills were frequently observed in bacteremic brucellosis patients, whereas arthritis was more common in nonbacteremic brucellosis patients. Serum CRP and PCT can be used as potential serological markers for diagnosing bacteremic brucellosis.

Keywords
Brucellosis, bacteremia, complication, C-reactive protein, procalcitonin, serological marker

Date received: 11 March 2020; accepted: 1 June 2020
Introduction

Brucellosis is a prevalent zoonotic disease worldwide and continuous to be a major public health problem.\textsuperscript{1,2} Brucellosis is caused by facultative intracellular pathogens of the genus \textit{Brucella}. Domestic and wild animals are considered natural reservoirs.\textsuperscript{3} The disease is mainly transmitted to humans by direct contact with infected animals or by consumption of unpasteurized milk and meat products derived from infected animals.\textsuperscript{4} Human brucellosis is a systemic infection that can affect various organ systems. Brucellosis typically causes abortion and sterility in animals and can have a variety of clinical presentations in humans including fever, sepsis, and multiple organ involvement.\textsuperscript{5,6} \textit{Brucella} species have unique epidemiological, phylogenetic and pathogenetic characteristics. One unique characteristic is the significance of bacteremia in the course of the disease.\textsuperscript{7}

Although bacteremic brucellosis is not uncommon, reports of bacteremic brucellosis are scarce. The clinical features and complications of this disease are unclear. The present study aimed to retrospectively investigate the epidemiological features, clinical manifestations and laboratory characteristics of bacteremic brucellosis.

Materials and methods

Brucellosis patients admitted to the Department of Infectious Diseases and Clinical Microbiology of Tianjin Second People’s Hospital between January 2015 and December 2017 were included in the study. A retrospective analysis was undertaken. Patient electronic medical records were reviewed for epidemiological features, clinical manifestations, and laboratory findings. The study was approved by the Medical Ethics Committee of our hospital. Written consent was obtained from each participant.

Brucellosis was diagnosed on the basis of one of the following criteria: (1) isolation of \textit{Brucella} species in blood; and (2) compatible clinical features, such as arthralgia, fever, sweating, chills, headache and malaise, supported by detection of specific antibodies at significant titers and/or demonstration of a fourfold or higher increase in antibody titer in serum specimens taken at 2- or 3-week intervals. Significant antibody titer were determined to be 1/160 or greater in agglutination tests.\textsuperscript{8} Patients with positive culture results for \textit{Brucella} species were classified as having bacteremic brucellosis and those with negative culture results for \textit{Brucella} species were classified as having non-bacteremic brucellosis. Therefore, nonbacteremic patients were diagnosed based on clinical features suggesting brucellosis as well as antibody titers and agglutination tests.

Blood culture samples were incubated in the Bact/Alert 3D system (BioMérieux, Marcy-l’Étoile, France) for up to 7 days. Typing of the bacteria was based on \textit{CO}$_2$ requirements, urease activity and growth on basic fuchsin and thionin dyes. \textit{Brucella} species were determined using standard biochemical methods. Blood samples were prepared according to the guidelines of different tests. Routine blood counts and measurements of CRP, PCT and blood chemistry were conducted for all patients. Blood counts were determined using a Sysmex XT-4000i instrument (Sysmex, Kobe, Japan). Serum CRP levels were quantitated using an immunoturbidimetric assay with a Lifotronic instrument (Shenzhen Lifotronic Technology Co., Shenzhen, China). Serum PCT measurements were performed using an electrochemiluminescence immunoassay and a Cobas immunoassay analyzer (Roche, Basel Switzerland). Blood chemistry was assessed using a Hitachi 7180 automatic analyzer (Hitachi, Tokyo, Japan). Clinical and laboratory data were collected from comprehensive electronic medical records.
Statistical analysis

Statistical analysis was performed using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA). For normally distributed variables, data were presented as means and standard deviations. Differences between continuous variables were assessed using the Student’s t-test for parametric data. Differences between categorical variables were assessed using the chi-square test. Values of $p < 0.05$ were considered statistically significant.

Results

Patient demographics

A total of 132 patients with brucellosis were enrolled in the study including 64 cases with bacteremic brucellosis (47 men, 73.4% and 17 women, 26.6%) and 68 cases with non-bacteremic brucellosis (58 men, 85.3% and 10 women, 14.7%). The mean age of bacteremic cases was $47.1 \pm 14.5$ years (range: 2–69 years) and the mean age of non-bacteremic cases was $47.5 \pm 14.4$ years (range: 3–70 years). The median duration from exposure to the onset of symptoms was 6.9 weeks (range: 1 day to 32 weeks) and 21.9 weeks (range: 1–76 weeks) in bacteremic and non-bacteremic cases, respectively ($p = 0.017$). The mode of transmission was considered to be: (1) consumption of unpasteurized milk and meat products from infected animals (17 patients, 12.9%) and (2) direct contact with animals or animal products (109 patients, 82.6%). No source of infection was identified for six patients (4.5%). The demographic and epidemiological characteristics of patients are shown in Table 1.

Clinical manifestations of brucellosis

The most frequent clinical manifestations were fever (78.0%) and chills (27.3%). More bacteremic than nonbacteremic patients presented with fever and chills as symptoms (fever, $p = 0.001$; chills, $p = 0.001$). Arthritis was observed in 25.8% of brucellosis patients and was significantly more common in nonbacteremic patients (35.3%) ($p = 0.010$). Orchitis was observed in 6.8% of patients and occurred in similar proportions of bacteremic and non-bacteremic cases (Table 2).

Laboratory characteristics of brucellosis patients

Significant elevations of serum CRP levels ($p = 0.001$) and thrombocytopenia ($p = 0.023$) were detected in bacteremic cases. Of the 132 patients, 11 (8.3%) had

| Table 1. Demographic and epidemiological characteristics of patients. |
|-------------------------------------------------|------------------|------------------|------------------|
| Characteristics | Nonbacteremic patients (n = 68) | Bacteremic patients (n = 64) | $p$ |
|------------------|---------------------------------|-----------------------------|-----|
| Sex (male/female) | 58/10                           | 47/17                       | 0.091 |
| Age (years)      | $47.5 \pm 14.5$                 | $47.1 \pm 14.4$             | 0.878 |
| Duration from exposure to onset of symptoms (weeks) | 21.9 (1 day to 32 weeks) | 6.9 (1–76) | 0.017 |
| Progression (acute/subacute/chronic) | 39/24/5                        | 48/16/0                     | <0.001 |
| Mode of transmission (n) |                                |                             | 0.651 |
| Ingestion of unpasteurized products | 7                              | 10                           | 0.835 |
| Direct contact with animals or animal products | 58                             | 51                           | 0.396 |
| Unidentified     | 3                               | 3                            | 0.939 |
anemia, eight (6.1%) had thrombocytope-
nia and 92 (69.7%) had normal blood cell
counts. Elevated liver enzyme levels were
detected in about 20% of patients with bru-
cellosis. The albumin levels of bacteremic
patients were slightly but significantly
lower than those of nonbacteremic patients
(37.43 ± 3.68 g/L vs. 39.97 ± 3.99 g/L)
(p = 0.001). The most frequent laboratory
findings were high serum CRP levels
(63.6%) in bacteremic patients. No eleva-
tion in serum PCT levels were observed in
either bacteremic or nonbacteremic patients
(Table 3).

**Diagnostic performance of serum
CRP and PCT**

Using serum CRP and PCT levels as sero-
logical markers, the areas under the receiver
operating characteristic curves were 0.64
[95% confidence interval (CI): 0.54–0.73] and
0.61 (95% CI: 0.51–0.70), respectively
(Figure 1).

**Discussion**

Brucellosis is a re-emerging bacterial zoo-
nosis that remains endemic in China.

Infections can cause serious complications,
and early diagnosis is important for optimal
prognosis. The gold standard for the diag-
nosis for brucellosis is identification of
*Brucella* species from blood or bone
marrow cultures. The rate of positive
blood cultures in brucellosis ranges from
15% to 90%. Clinically, brucellosis may
occur as an acute (less than 2 months), sub-
acute (2 months to 12 months) or chronic
(more than 12 months) infection. Blood cul-
ture results vary depending on disease pro-
gression. Consistent with previous studies,
we found that acute brucellosis was usually
associated with a high rate of *Brucella*
bacteremia.

Brucellosis is a systemic infection and
subacut

| Table 2. Comparison of clinical manifestations of brucellosis patients. |
|-----------------------------------------------|
| Clinical manifestations | Nonbacteremic patients (n = 68) | Bacteremic patients (n = 64) | p     |
| Symptons, n (%)          |                               |                                |       |
| Fever                    | 44 (64.7%)                    | 59 (92.2%)                     | 0.0001 |
| Chills                   | 8 (11.8%)                     | 28 (43.8%)                     | <0.0001|
| Arthritis                | 24 (35.3%)                    | 10 (15.6%)                     | 0.010  |
| Testicular pain          | 2 (2.9%)                      | 7 (10.9%)                      | 0.069  |
| Encephalitis             | 1 (1.5%)                      | 1 (1.6%)                       | 0.966  |
| Jaundice                 | 4 (5.9%)                      | 6 (3.6%)                       | 0.930  |
| Signs, n (%)             |                               |                                |       |
| Fever                    | 44 (64.7%)                    | 58 (90.6%)                     | 0.0004 |
| Arthritis                | 22 (32.4%)                    | 9 (14.1%)                      | 0.007  |
| Encephalitis             | 1 (1.5%)                      | 1 (1.6%)                       | 0.966  |
| Orchitis                 | 2 (2.9%)                      | 7 (10.9%)                      | 0.069  |
| Jaundice                 | 5 (7.4%)                      | 4 (6.3%)                       | 0.802  |
Early assessment of the risk of brucellosis relies on information derived from clinical examinations and laboratory findings. Of the 132 patients studied here, 8.3% had anemia, 6.1% had thrombocytopenia and 70.0% had normal blood cell counts. A slight elevation of liver enzyme levels could be detected in approximately 20%
of all patients with brucellosis. Elevated liver enzyme levels are usually subclinical and jaundice is rare. Elevated alanine aminotransferase levels returned to normal in all patients when treatment was finished. We observed lower albumin and platelet count in bacteremic patients compared with nonbacteremic patients, which might occur because liver and bone marrow dysfunction is more severe in bacteremic patients.

Inflammatory markers measured in the clinical assessment of brucellosis patients often provide useful information. Serum CRP and PCT are classic serological markers of inflammation and are used to monitor the progress of infection. CRP is a sensitive but nonspecific biomarker of systemic inflammation, and is synthesized in the acute phase of inflammatory responses. Elevated CRP levels are associated with brucellosis and might be useful to diagnose acute brucellosis. Compared with nonbacteremic cases, elevated CRP levels were detected significantly more often in bacteremic cases. As a nonspecific inflammatory marker, CRP alone is a suboptimal predictive factor for Brucella infection, although more than 60% of patients with brucellosis show CRP elevation.

PCT, a precursor of the hormone calcitonin, is synthesized by thyroid C cells and generally has low levels in healthy individuals. PCT production in various tissues occurs in inflammatory processes such as sepsis, severe systemic bacterial infections, malaria and some fungal infections. PCT levels >0.5 ng/mL are usually considered as diagnostically relevant for most bacterial infections. Our findings revealed that all brucellosis patients had normal levels of PCT irrespective of their blood culture results. This suggested that PCT levels in brucellosis may be specific but not sensitive for Brucella bacteremia. A previous receiver operating characteristic curve analysis of PCT levels in Brucella bacteremia suggested that PCT was not sufficiently sensitive in diagnosing Brucella bacteremia, but could be useful for excluding Brucella bacteremia.

In conclusion, patients with Brucella bacteremia presented early in their course of illness. Their clinical features and laboratory characteristics, however, did not differ from nonbacteremic brucellosis patients. Fever and chills were frequently observed in bacteremic brucellosis patients, whereas arthritis was more often observed in nonbacteremic brucellosis patients. Liver and bone marrow dysfunction was more severe in bacteremic patients than nonbacteremic patients.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Chunhua Qie https://orcid.org/0000-0002-1955-7250

References
1. Keşli R, Bilgin H and Yılmaz H. Determination of in vitro susceptibilities of Brucella spp. strains against 11 different antibacterial gents isolated from blood cultures. Mikrobiyol Bul 2017; 51: 260–268.
2. Chand P, Chhabra R and Nagra J. Vaccination of adult animals with a reduced dose of Brucella abortus S19 vaccine to control brucellosis on dairy farms in endemic areas of India. Trop Anim Health Prod 2015; 47: 29–35.
3. Pappas G, Akritidis N, Bosilkovski M, et al. Brucellosis. N Engl J Med 2005; 352: 2325–2336.
4. Kursun E, Turunc T, Demiroglu Y, et al. Evaluation of four hundred and forty seven brucellosis cases. *Intern Med* 2013; 52: 745–750.

5. Memish Z, Mah MW, Al Mahmoud S, et al. *Brucella* bacteraemia: clinical and laboratory observations in 160 patients. *J Infect* 2000; 40: 59–63.

6. Doganay M and Aygen B. Human brucellosis: an overview. *Int J Infect Dis* 2003; 7: 173–182.

7. Pappas G and Papadimitriou P. Challenges in *Brucella* bacteraemia. *Int J Antimicrob Agents* 2007; 30: S29–S31.

8. Young EJ. Serologic diagnosis of human brucellosis: analysis of 214 cases by agglutination tests and review of the literature. *Rev Infect Dis* 1991; 13: 359–372.

9. Karthik K, Rathore R, Thomas P, et al. Loop-mediated isothermal amplification (LAMP) test for specific and rapid detection of *Brucella abortus* in cattle. *Vet Q* 2014; 34: 174–179.

10. Yagupsky P. Detection of brucella in blood cultures. *J Clin Microbiol* 1999; 37: 3437–3442.

11. Apa H, Devrim I, Memur S, et al. Factors affecting *Brucella* spp. blood cultures positivity in children. *Vector Borne Zoonotic Dis* 2013; 13: 176–180.

12. Dokuzoğuz B, Ergönül O, Baykam N, et al. Characteristics of *B. melitensis* versus *B. abortus* bacteraemias. *J Infect* 2005; 50: 41–45.

13. Buzgan T, Karahocagil MK, Irmak H, et al. Clinical manifestations and complications in 1028 cases of brucellosis: a retrospective evaluation and review of the literature. *Int J Infect Dis* 2010; 14: e469–e478.

14. Kadanali A, Ozden K, Altoparlak U, et al. Bacteremic and nonbacteremic brucellosis: clinical and laboratory observations. *Infection* 2009; 37: 67–69.

15. Liu J and Zhao X. Clinical features and serum profile of inflammatory biomarkers in patients with brucellosis. *J Infect Dev Ctries* 2017; 11: 840–846.

16. Kadanali A, Ozkurt Z, Albayrak A, et al. An unusual presentation of acute brucellosis with fever, jaundice and maculopapular rash. *Int J Infect Dis* 2006; 10: 409–410.

17. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. *Adv Clin Chem* 2009; 48: 111–136.

18. Povoa P. C-reactive protein: a valuable marker of sepsis. *Intensive Care Med* 2002; 28: 235–243.

19. Navarro JM, Mendoza J, Leiva J, et al. C-reactive protein as a prognostic indicator in acute brucellosis. *Diagn Microbiol Infect Dis* 1990; 13: 269–270.

20. Yuan LY, Ke ZQ, Wang M, et al. Procalcitonin and c-reactive protein in the diagnosis and prediction of spontaneous bacterial peritonitis associated with chronic severe hepatitis B. *Ann Lab Med* 2013; 33: 449–454.

21. Dou YH, Du JK, Liu HL, et al. The role of procalcitonin in the identification of invasive fungal infection-a systemic review and meta-analysis. *Diagn Microbiol Infect Dis* 2013; 76: 464–469.

22. Righi E, Merelli M, Arzese A, et al. Determination of PCT on admission is a useful tool for the assessment of disease severity in travelers with imported *Plasmodium falciparum* malaria. *Acta Parasitol* 2016; 61: 412–418.

23. Kibe S, Adams K and Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. *J Antimicrob Chemother* 2011; 66: 33–40.

24. Kaklikkaya N, Bayramoglu G, Buruk K, et al. Determination of procalcitonin levels in *Brucella* and *Salmonella* bacteremia. *Nobel Med* 2013; 9: 116–119.